Last C$16.22 CAD
Change Today +0.89 / 5.81%
Volume 42.9K
TKM On Other Exchanges
As of 4:00 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

tekmira pharmaceuticals corp (TKM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - C$34.66
52 Week Low
12/18/13 - C$7.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

tekmira pharmaceuticals corp (TKM) Related Businessweek News

View More BusinessWeek News

tekmira pharmaceuticals corp (TKM) Details

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.

tekmira pharmaceuticals corp (TKM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $377.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $69.5K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $305.9K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $233.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $128.6K
Compensation as of Fiscal Year 2013.

tekmira pharmaceuticals corp (TKM) Key Developments

Tekmira Pharmaceuticals Corporation Announces Earnings Results for the Nine Months Ended September 30, 2014

Tekmira Pharmaceuticals Corporation announced earnings results for the nine months ended September 30, 2014. For the period, the company reported net loss of $32.67 million or $1.53 loss per share compared to $11.46 million or $0.79 loss per share for the same period ended September 30, 2013. Total revenue was $10.6 million compared to $7.94 million for the same period ended September 30, 2013.

Dicerna Pharmaceuticals, Inc. Enters into License Agreement and Development and Supply Agreement with Protiva Biotherapeutics Inc. and Tekmira Pharmaceuticals Corporation

On November 16, 2014 Dicerna Pharmaceuticals, Inc., a Delaware corporation (Dicarna), entered into a License Agreement and a Development and Supply Agreement with Protiva Biotherapeutics Inc. (Protiva) and Tekmira Pharmaceuticals Corporation (Tekmira). Under the terms of the License Agreement, Protiva and Tekmira grant Dicerna an exclusive (except with respect to previously granted license rights), worldwide license to use Protiva and Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of certain therapeutics to treat primary hyperoxaluria type 1 (PH1). During the term of the License Agreement, Dicerna will not in-license from a third party for use with a licensed product a drug delivery system competitive with Protiva's LNP technology, provided, however, that if Dicerna in-licenses such a delivery system from a third party after the first commercial sale of a licensed product, the license grant of the LNP technology to Dicerna will thereafter be on a non-exclusive basis. Dicerna made an upfront payment of $2,500,000 in connection with the signing of the License Agreement. Dicerna will make potential total development and approval milestone payments of $22,000,000. Dicerna is also required to pay a mid-single digit percentage royalty on all net sales of licensed products during the royalty period. The royalty period in a country is the longer of the expiration of the data exclusivity granted by the country's regulatory authority, the last to expire of certain patent claims applicable to products sold in such country, and the 10 year anniversary of the commencement of commercial sales in such country. The License Agreement may be terminated if: either party commits a material, uncured breach, Dicerna does not use commercially reasonable efforts to develop or commercialize the licensed product, Dicerna commences an action challenging the validity of the licensed patents; or if either party initiates bankruptcy, liquidation or similar proceedings. Contemporaneously with the execution of the License Agreement, Dicerna, Protiva and Tekmira entered into the Development and Supply Agreement. Under the terms of the Development and Supply Agreement, Protiva will perform certain development and other services for Dicerna and manufacture and test licensed products for Dicerna, including: the manufacture of all licensed products for pre-clinical testing and development, design of the final licensed product formulation to be used as the clinical development candidate, manufacture of the final formulated licensed product for clinical trials, assistance in the preparation of regulatory submissions and interactions with the FDA and its foreign equivalents, and performing technical transfer to Dicerna's selected contract manufacturer for the licensed product. Dicerna will pay Protiva on a time and materials basis at an agreed upon FTE rate and with an administrative mark-up on the acquisition of materials. The Development and Supply Agreement provides that intellectual property developed by a single party pursuant to activities contemplated by the agreement and not based on the practice of certain confidential information or intellectual property of the other party or directed solely to the other party's materials provided pursuant to the agreement shall be owned by such party. The agreement provides for joint ownership of certain jointly developed intellectual property as well as joint or collaborative prosecution, maintenance, and defense of such intellectual property.

Dicerna Announces License Agreement with Tekmira to Advance Dicerna's PH1 Development Program

Dicerna Pharmaceuticals Inc. announced a licensing agreement for Dicerna to use Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna's investigational product candidate for primary hyperoxaluria type 1 (PH1), a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. This announcement follows the successful testing of DCR-PH1 in combination with Tekmira's LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront, as well as $22 million in potential development milestones, and a mid-single-digit royalty on future PH1 sales Tekmira's LNP system has shown in other human clinical studies to provide potent, safe and effective RNA delivery to hepatocytes (liver cells). Licensing Tekmira's LNP will streamline the development path for DCR-PH1 and allows Dicerna to focus its LNP efforts on its oncology pipeline.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKM:CN C$16.22 CAD +0.89

TKM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.87 AUD -0.045
Galena Biopharma Inc $1.63 USD +0.10
Marina Biotech Inc $0.60 USD 0.00
Prosensa Holding NV $18.48 USD -0.07
Silence Therapeutics PLC 200.00 GBp +5.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TKM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEKMIRA PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at